PL1981516T3 - Zastosowanie mikroorganizmów probiotycznych w leczeniu i zapobieganiu otyłości i pokrewnym zaburzeniom - Google Patents

Zastosowanie mikroorganizmów probiotycznych w leczeniu i zapobieganiu otyłości i pokrewnym zaburzeniom

Info

Publication number
PL1981516T3
PL1981516T3 PL07734501T PL07734501T PL1981516T3 PL 1981516 T3 PL1981516 T3 PL 1981516T3 PL 07734501 T PL07734501 T PL 07734501T PL 07734501 T PL07734501 T PL 07734501T PL 1981516 T3 PL1981516 T3 PL 1981516T3
Authority
PL
Poland
Prior art keywords
obesity
prevention
treatment
related disorders
probiotic microorganisms
Prior art date
Application number
PL07734501T
Other languages
English (en)
Inventor
Nina Rautonen
Heli Putaala
Arthur Ouwehand
Kirsti Tiihonen
Marta Zdzislawa Korczynska
Wouter Herman Noordman
Original Assignee
Dupont Nutrition Biosciences Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dupont Nutrition Biosciences Aps filed Critical Dupont Nutrition Biosciences Aps
Publication of PL1981516T3 publication Critical patent/PL1981516T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
    • A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Birds (AREA)
  • Animal Husbandry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Child & Adolescent Psychology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
PL07734501T 2006-01-27 2007-01-26 Zastosowanie mikroorganizmów probiotycznych w leczeniu i zapobieganiu otyłości i pokrewnym zaburzeniom PL1981516T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US76249106P 2006-01-27 2006-01-27
EP07734501.5A EP1981516B1 (en) 2006-01-27 2007-01-26 Use of probiotic microorganisms for the treatment and prevention of obesity and related disorders
PCT/IB2007/001186 WO2007085970A2 (en) 2006-01-27 2007-01-26 Use of probiotic microorganisms for the treatment and prevention of obesity and related disorders

Publications (1)

Publication Number Publication Date
PL1981516T3 true PL1981516T3 (pl) 2019-03-29

Family

ID=38309585

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07734501T PL1981516T3 (pl) 2006-01-27 2007-01-26 Zastosowanie mikroorganizmów probiotycznych w leczeniu i zapobieganiu otyłości i pokrewnym zaburzeniom

Country Status (11)

Country Link
US (1) US8257695B2 (pl)
EP (1) EP1981516B1 (pl)
JP (1) JP2009524640A (pl)
CN (1) CN101410128A (pl)
BR (1) BRPI0707336A2 (pl)
DK (1) DK1981516T3 (pl)
ES (1) ES2693584T3 (pl)
MX (1) MX2008009726A (pl)
PL (1) PL1981516T3 (pl)
RU (1) RU2008134892A (pl)
WO (1) WO2007085970A2 (pl)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010534074A (ja) * 2007-07-25 2010-11-04 カンピナ ネーデルランド ホールディング ビー．ブイ． 飽和および／または充足を誘発するプロバイオティックス
EP2030623A1 (en) * 2007-08-17 2009-03-04 Nestec S.A. Preventing and/or treating metabolic disorders by modulating the amount of enterobacteria
DK2209527T3 (da) 2007-10-11 2013-03-18 Dupont Nutrition Biosci Aps Farmaceutiske sammensætninger omfattende L-acidophilus og Bifidobacterium lactis til anvendelse i behandlingen af funktionel tarmsygdom
ATE537707T1 (de) * 2008-05-16 2012-01-15 Nestec Sa Lactobacillus paracasei und gewichtskontrolle
US20110189149A1 (en) * 2008-06-20 2011-08-04 Remy Burcelin New Uses of Lactic Acid Bacteria and Bifidobacteria
ATE489856T1 (de) 2009-01-06 2010-12-15 Rosebud Ag Symbiotische zusammensetzung und ihr herstellungsverfahren
WO2010104242A1 (ko) * 2009-03-10 2010-09-16 주식회사 지니스 미생물을 이용한 비만 및 비만으로 야기된 대사성 질환의 예방과 치료
PL2411027T3 (pl) * 2009-03-25 2015-04-30 Chr Hansen As Zastosowanie probiotyku do regulowania masy ciała
US20120027737A1 (en) * 2009-03-25 2012-02-02 Chr-Hansen A/S Use of probiotics to ameliorate diet-induced insulin resistance
EP2308499A1 (en) * 2009-09-30 2011-04-13 Nestec S.A. Bifidobacterium longum ATCC BAA-999 (BL999) and weight control
FR2955774A1 (fr) 2010-02-02 2011-08-05 Aragan Preparation destinee a traiter l'exces ponderal et les desordres associes et applications de ladite preparation
WO2011148220A1 (en) * 2010-05-28 2011-12-01 Compagnie Gervais Danone Probiotic strains for use in improving transepithelial resistance
ES2389547B1 (es) 2010-12-07 2013-08-08 Consejo Superior De Investigaciones Científicas (Csic) Bifidobacterium cect 7765 y su uso en la prevención y/o tratamiento del sobrepeso, la obesidad y patologías asociadas.
CN102670661B (zh) * 2011-03-08 2013-10-02 惠宏襄 用于刺激胰高血糖素样肽-1分泌的药物
JP2013147457A (ja) * 2012-01-19 2013-08-01 Yakult Honsha Co Ltd メタボリックシンドローム予防改善剤
EP2645099A1 (en) * 2012-03-30 2013-10-02 Phares Pharmaceutical Research N.V. Biorelevant compositions
EP3593811A1 (en) * 2012-09-20 2020-01-15 Prothera, Inc. Probiotic compositions and methods for the treatment of obesity and obesity-related conditions
US10022407B2 (en) * 2012-11-12 2018-07-17 Compagnie Gervais Danone Use of a lactobacillus rhamnosus strain for reducing weight gain and/or insulin resistance
BR112015010639A2 (pt) * 2012-11-12 2017-07-11 Biopolis SL lactobacillus rhamnosus para redução da acumulação de gordura corporal
CA2907525A1 (en) * 2013-03-28 2014-10-02 Nestec S.A. Indoxyl sulfate as a biomarker of prebiotic efficacy for weight gain prevention
EP2979088B1 (en) * 2013-03-28 2018-05-16 Nestec S.A. Alpha-keto-isovalerate as a biomarker of prebiotic efficacy for weight gain prevention
EP3007723A1 (en) * 2013-06-12 2016-04-20 University College Cork, National University Of Ireland Bile salt hydrolase bsh1 for regulating weight gain, serum cholesterol levels, and liver triglycerides in a mammal; bacteria strains expressing bsh1 variants
KR102332078B1 (ko) * 2013-12-05 2021-11-26 인스티튜트 내셔널 드 라 싼테 에 드 라 리셰르셰 메디칼르 (인 썸) 알파-MSH의 ClpB 단백질 모방을 통한 식욕의 조절에 대한 세균 영향
US10729770B2 (en) 2013-12-05 2020-08-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) Bacterial influence on regulation of appetite via ClpB protein mimicry of alpha-MSH
WO2015121455A1 (fr) * 2014-02-14 2015-08-20 Vesale Pharma Sa Composition comprenant au moins un probiotique
WO2015121458A2 (fr) * 2014-02-14 2015-08-20 Vesale Pharma Sa Composition comprenant du bifidobacterium animalis ssp. lactis
BE1000016B1 (fr) * 2014-04-25 2016-02-01 Vesale Pharma Nv Composition comprenant du bifidobacterium animalis ssp. lactis.
EP3104868A2 (fr) * 2014-02-14 2016-12-21 Vesale Pharma Sa Utilisations de compositions comprenant du bifidobacterium animalis ssp. lactis lmg p-28149
BE1000017B1 (fr) * 2014-04-25 2016-01-21 Vesale Pharma Nv Composition comprenant au moins un probiotique
EP3200814B1 (en) * 2014-10-02 2020-09-23 INSERM - Institut National de la Santé et de la Recherche Médicale Food compositions for inducing satiation and prolonging satiety in subjects in need thereof
EP3881680A1 (en) 2014-10-31 2021-09-22 Pendulum Therapeutics, Inc. Methods and compositions relating to microbial treatment
KR102125548B1 (ko) 2015-02-10 2020-06-24 주식회사 지니스 비만 억제능을 갖는 균주 및 이를 함유하는 약학 조성물
KR20160116252A (ko) 2015-03-27 2016-10-07 전남대학교산학협력단 비환원성 말단의 불포화형 만뉴론산 올리고당 및 이를 유효성분으로 포함하는 조성물
EP3302517B1 (en) * 2015-06-05 2020-09-23 Institut National de la Sante et de la Recherche Medicale (INSERM) Food compositions for inducing satiation and prolonging satiety in subjects in need thereof
JP6813974B2 (ja) * 2016-07-14 2021-01-13 株式会社明治 グレリン分泌促進剤
RU2758969C2 (ru) * 2017-05-22 2021-11-03 Компани Жервэ Данон КОМПОЗИЦИИ И СПОСОБЫ УМЕНЬШЕНИЯ ПОПУЛЯЦИИ Bilophila wadsworthia ИЛИ ИНГИБИРОВАНИЯ ЕЕ РОСТА
CA3073838A1 (en) 2017-08-30 2019-03-07 Pendulum Therapeutics, Inc. Methods and compositions for treatment of microbiome-associated disorders
CN112823015A (zh) * 2018-08-01 2021-05-18 N.M.B.医学应用有限公司 减少卡路里的吸收和改变所消耗的营养物的营养价值的口服施用的补充剂及方法
KR102616412B1 (ko) * 2021-07-30 2023-12-21 주식회사 메디오젠 비피도박테리움 애니말리스 락티스 mg741 균주를 포함하는 비만 또는 비알콜성 지방간 예방 또는 치료용 조성물
KR20230112214A (ko) * 2022-01-20 2023-07-27 주식회사 쎌바이오텍 프로바이오틱스 유래 배양여과물을 포함하는 항노화 화장료 조성물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2111625T3 (es) 1992-07-06 1998-03-16 Nestle Sa Agente antigastritis.
JP2001292728A (ja) * 2000-04-13 2001-10-23 Enajikku Kk 肥満防止食品
JP4580542B2 (ja) * 2000-05-17 2010-11-17 株式會社バイオニア 肥満又は糖尿病治療用微生物及びその微生物を含む医薬組成物
SE0004124D0 (sv) * 2000-11-10 2000-11-10 Probi Ab New use
EP1408760B1 (en) * 2001-02-19 2009-04-01 Société des Produits Nestlé S.A. Consumable product containing probiotics
CN1372201A (zh) * 2002-04-03 2002-10-02 张平 一种网络安全新方法
US6942857B2 (en) * 2002-08-09 2005-09-13 Bioneer Corporation Microorganisms for preventing and/or treating obesity or diabetes mellitus
JP2005013211A (ja) * 2002-09-27 2005-01-20 Wakamoto Pharmaceut Co Ltd 乳酸菌含有食品組成物
AU2003285937A1 (en) * 2002-10-22 2004-05-13 University Of Vermont And State Agriculture College Symbiotic food products comprising oats and methods for manufacturing the same
US7001756B1 (en) * 2004-02-19 2006-02-21 Genmont Biotech Inc. Microorganism strain of GM-020 of Lactobacillus rhamnosus and its use for treating obesity
KR100686558B1 (ko) * 2004-09-02 2007-02-23 씨제이 주식회사 체지방 저하 기능성 락토바실러스 플랜타륨와 이를 함유한 식품
WO2006052135A2 (en) * 2004-11-15 2006-05-18 Nizo Food Research B.V. Satiety enhancing compositions
SE529185C2 (sv) * 2005-10-07 2007-05-22 Arla Foods Amba Användning av probiotiska bakterier för tillverkning av livsmedel eller läkemedel för förhindrande av övervikt

Also Published As

Publication number Publication date
US8257695B2 (en) 2012-09-04
WO2007085970A3 (en) 2008-05-08
CN101410128A (zh) 2009-04-15
ES2693584T3 (es) 2018-12-12
EP1981516A2 (en) 2008-10-22
BRPI0707336A2 (pt) 2011-05-03
WO2007085970A2 (en) 2007-08-02
US20100061967A1 (en) 2010-03-11
MX2008009726A (es) 2009-03-05
DK1981516T3 (en) 2018-12-03
JP2009524640A (ja) 2009-07-02
EP1981516B1 (en) 2018-08-08
RU2008134892A (ru) 2010-03-10

Similar Documents

Publication Publication Date Title
PL1981516T3 (pl) Zastosowanie mikroorganizmów probiotycznych w leczeniu i zapobieganiu otyłości i pokrewnym zaburzeniom
IL258730A (en) Preparations and methods for the treatment of microbial disorders
GB0610350D0 (en) prevention and/or treatment of neuodegenerative disorders
EP2043727A4 (en) DEVICES AND METHOD FOR THE TREATMENT OF ADIPOSITAS
HK1126212A1 (en) Heterocyclic compounds and uses thereof in the treatment of sexual disorders
IL195819A0 (en) Modulators of metabolism and the treatment of disorders related thereto
ZA200900055B (en) Modulators of metabolism and the treatment of disorders related thereto
ZA200807936B (en) Compounds for the treatment of spinal muscular atrophy and other uses
ZA200706238B (en) Prevention and treatment of thromboembolic disorders
EP2087094A4 (en) LACTOBACILLUS FERMENTUM ESS-1, DSM17851 AND ITS USE IN THE TREATMENT AND / OR PREVENTION OF CANDIDOSIS AND URINARY TRACT INFECTIONS
EP1988777A4 (en) PYRAZOLE FOR THE TREATMENT OF ADIPOSITAS AND OTHER CNS DISEASES
EP2194917A4 (en) DEVICES AND METHODS FOR THE TREATMENT OF OBESITY
IL195906A0 (en) Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
IL193936A0 (en) Compositions and methods for the treatment of immunoinflammatory disorders
EP1996218A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS
IL192025A0 (en) Novel n-sulfamoyl-piperidineamides for the prophylaxis or treatment of obesity and related conditions
IL211459A0 (en) Pancreatic polypeptide and variants thereof for use in the treatment of intestinal disorders
EP2004216A4 (en) AGENT FOR THE TREATMENT OF HORMONO-DEPENDENT DISORDERS AND USES THEREOF
IL202523A0 (en) Buspirone for the treatment of mausea and vomiting
IL193799A0 (en) New therapeutic combinations for the treatment or prevention of psycotic disorders
EP2231146A4 (en) Pharmaceutical composition for the treatment and prevention of glaucoma
EP2285398A4 (en) METHOD AND COMPOSITIONS FOR TREATING ADIPOSITAS
IL193943A0 (en) The use of beta- aminoalcohols for the treatment of inflammatory disorders and pain
IL193944A0 (en) The use beta-aminoalcohols for the treatment of inflammatory disorders and pain
IL188056A0 (en) Use of allylmercaptocaptopril for treating or preventing obesity and obesity related diseases